OCC is another same same (reminder to self) for bloke.
BOT - Botanix Pharmaceuticals
- Thread starter alex90
- Start date
https://www.aussiestockforums.com/threads/occ-orthocell-limited.28698/
door-knock 4 cr? ..... who cares why ....there will be trades in it here (but i already know that ...... so seems a pointless post)
where is barney when i need a laugh?
(post june xjo is the thing i have no idea about - should i load long or will history just repeat?)
door-knock 4 cr? ..... who cares why ....there will be trades in it here (but i already know that ...... so seems a pointless post)
where is barney when i need a laugh?
(post june xjo is the thing i have no idea about - should i load long or will history just repeat?)
- Joined
- 30 June 2007
- Posts
- 7,200
- Reactions
- 1,226
Another small biotech with nothing. People should never hold these as investments, and yet it's obvious they do. Trade them early when the sentiment is positive and dump into the strength.
- Joined
- 2 May 2007
- Posts
- 4,707
- Reactions
- 2,937
How about their moving into phase 3 trial? Any merit in that news or hoax?
Market reacted very sharply today on negative side. So honestly dont understand this reaction. Must be something more.
- Joined
- 30 June 2007
- Posts
- 7,200
- Reactions
- 1,226
BTX 1503 didn't beat placebo in the US, so I have no idea why they'd want to do a phase 3. I don't know what they're thinking.
The Aus figures show just how useless the scientific process is when it comes to drug trials (26% versus 41%, just by changing the location of the trial!). There's a guy in the US who has some very interesting ideas on placebo and its mechanisms. His experiments suggest it's a resonance effect, rather than (or as well as) expectation. If he's correct, it would throw big pharma into a tail spin they'll never recover from.
Speaking generally, science in medicine isn't what it's cracked up to be. The whole book needs to be re-written. Compared to advances in engineering, IT, transport, farming, etc. over the same time frames, they have very little to show for all the billions that are spent in research.
Last edited:
- Joined
- 2 May 2007
- Posts
- 4,707
- Reactions
- 2,937
Alan Kohler also raised eye brow on Botanix.
Dona Ferentes
Abrió la caja, vio al gatito, y sonrió
- Joined
- 11 January 2016
- Posts
- 15,587
- Reactions
- 21,192
no announcement since 25/3. Speeding ticket tomorrow?
- Joined
- 16 April 2020
- Posts
- 80
- Reactions
- 76
Will Botanix’s FDA green light for their BTX1801 lead to big things or just another pointless clinical trial? Thoughts anyone.
- Joined
- 2 May 2007
- Posts
- 4,707
- Reactions
- 2,937
@Colm Doc first of all congratulations for making a decision to join on this fantastic group of ASF. I noticed less than 10 days you have posted 8 times and got 25% likings - must be a wanted poster
. Keep it up. We need active participants.I saw the graph you presented and sorry not being following up the progress of BOT off late.
My two cents : your graph tells the story and probably some factoring done prior to FDA approval.
So in essence on Tuesday, my speculation is BOT will only go north by leaps and bounds. On 24th April, market welcomed by 61% increase in price and some 80 times volume increase. I am sure BOT holders are opening champagne bottles. Probably many more would join on Tuesday. Good luck
- Joined
- 2 May 2007
- Posts
- 4,707
- Reactions
- 2,937
@Austwide - sorry. I was so wrong for Monday. But guess what , I could be still right for Tuesday compared to Monday's prices
Did not realise Monday was not a holiday in East Coast.
greggles
I'll be back!
- Joined
- 28 July 2004
- Posts
- 4,475
- Reactions
- 4,537
BOT has recovered very well since its share price collapse in March 2020 when it fell to a low of 2.2c. Today it has reached a high of 19c and looks set to break through the 20c mark.
Results from the TX 1801 Phase 2a Study were announced today and the market liked what the company reported:
Results from the TX 1801 Phase 2a Study were announced today and the market liked what the company reported:
- Top-line data showed that two different BTX 1801 formulations (ointment and gel) were safe, well tolerated and successful at eradicating Staphylococcus aureus.
- Eradication rates as high as 76.2% were obtained at Day 7 for BTX 1801 ointment, with eradication effects extending through to Day 28 of the study to 23.8%, despite no treatment after Day 5
- Botanix continues to assess the clinical utility of synthetic CBD for the treatment of a variety of infections and also develop its proprietary CBD analog assets
- Joined
- 16 April 2020
- Posts
- 80
- Reactions
- 76
Yeah, great news today. How long do you think it will take them to bring any of their projects to commercial point?
greggles
I'll be back!
- Joined
- 28 July 2004
- Posts
- 4,475
- Reactions
- 4,537
It's difficult to predict, but these latest results have just served to de-risk BOT substantially in the eyes of the market.
I imagine there would be quite a few large cap pharmaceutical companies keen to get into the cannabis space taking a serious look at BOT.
Jazz Pharmaceuticals just bought a cannabinoid drug maker for $7.2 billion.
- Joined
- 26 September 2021
- Posts
- 1
- Reactions
- 1
I am new to this stock having been recommended it by a friend but the recent hiring looks like it might be a good thing.
Dona Ferentes
Abrió la caja, vio al gatito, y sonrió
- Joined
- 11 January 2016
- Posts
- 15,587
- Reactions
- 21,192
...wot BOT doing?
no idea, but 9c oppies are being exercised and buying has been there recently.
no idea, but 9c oppies are being exercised and buying has been there recently.
Dona Ferentes
Abrió la caja, vio al gatito, y sonrió
- Joined
- 11 January 2016
- Posts
- 15,587
- Reactions
- 21,192
BOT attacking the market
Highlights:
• Patient Experience Program underway with first prescriptions issued and Sofdra delivered to patients
• Inventory build and logistics infrastructure testing completed to support full commercial launch in Q1 2025
• Marketing and sales materials developed, tested and refined
• Sales force engaged and preparing for launch meeting in late January, followed by digital program expansion
Philadelphia PA and Phoenix AZ - 17 December 2024:
Clinical dermatology company, Botanix Pharmaceuticals Ltd, is very pleased to announce that first prescriptions for Sofdra™ (sofpironium) topical gel, 12.45% have shipped to patients, after having successfully been diagnosed via telemedicine and cleared insurance approvals.
all sounds very wonderful.
Somebody's buying it:
First Sofdra™ Prescriptions as Commercialisation Ramps Up
Highlights:
• Patient Experience Program underway with first prescriptions issued and Sofdra delivered to patients
• Inventory build and logistics infrastructure testing completed to support full commercial launch in Q1 2025
• Marketing and sales materials developed, tested and refined
• Sales force engaged and preparing for launch meeting in late January, followed by digital program expansion
Philadelphia PA and Phoenix AZ - 17 December 2024:
Clinical dermatology company, Botanix Pharmaceuticals Ltd, is very pleased to announce that first prescriptions for Sofdra™ (sofpironium) topical gel, 12.45% have shipped to patients, after having successfully been diagnosed via telemedicine and cleared insurance approvals.
all sounds very wonderful.
Somebody's buying it:
